Drug Trial Radar · NCT01176266
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
Last checked: Nov 20, 2026Latest source record: Mar 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Jul 2010
Primary completion
Sep 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Aug 5, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 minute, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of a study drug called asfotase alfa (human recombinant tissue non-specific alkaline phosphate fusion protein) to see what effects it has on patients 5 years of age or less with HPP.
Conditions
- Hypophosphatasia
Interventions
asfotase alfaDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP)Time frame: From Baseline to Week 24
- Safety and Tolerability of Repeated Subcutaneous (SC) Injections of Asfotase AlfaTime frame: Up to 72 months or until regulatory approval in the country of residence. Patients received study drug for a median duration of 829.0 days, with a range from 6 to 2116 days (ie, from 0.9 week to 5.8 years).
Locations
23 sites in 12 countries. Site status is shown where the registry gives one.
Children's Hospital & Research Center Oakland
Oakland, California
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Lady Cilento Children's Hospital
South Brisbane, Queensland, Australia
Royal Children'S Hospital Melbourne
Parkville, Victoria, Australia
Health Sciences Centre Winnipeg, University of Manitoba
Winnipeg, Manitoba, Canada
Necker Hospital
Paris, France
Chu de Toulouse
Toulouse, France
Universitätskinderklinikum Würzburg
Würzburg, Germany
Istituto Giannina Gaslini
Genova, Italy
Ospedale Pediatrico Bambino Gesù
Roma, Italy
Saitama Municipal Hospital
Saitama, Japan
Fukuoka Higashi Medical Hospital
Koga, Fukuoka, Japan
Ishikawa Prefectural Hospital
Kanazawa, Ishikawa-ken, Japan
St. Marianna University School of Medicine, Yokohayama City Seibu Hospital
Yokohama, Kanagawa, Japan
Tokyo Medical University Hospital
Shinjuku, Tokyo, Japan
Federal State Budgetary Institution
Moscow, Russia
King Faisal Specialist Hospital and Research Center
Riyadh, Saudi Arabia
Hospital Infantil Universitario Nino Jesus
Madrid, Spain
Uludag University
Bursa, Turkey (Türkiye)
Birmingham Children's Hospital
Birmingham, United Kingdom
Royal Manchester Children'S Hospital
Manchester, United Kingdom
Sheffield Children'S Hospital
Sheffield, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.